Advertisement


Patrick Goodley, MBBChir, MRCP: What Is the Optimal Upper Age Limit for Lung Cancer Screening?

IASLC WCLC 2025

Advertisement

Patrick Goodley, MBBChir, MRCP, of Manchester University NHS Foundation Trust, reports results from a study that looked at treatment and survival rates in people aged 75 to 80 years diagnosed with screen-detected lung cancer in two targeted lung cancer screening implementation settings (Abstract PL03.19). 



Related Videos

Lung Cancer

Alexander Drilon, MD, on ROS1 Fusion–Positive NSCLC: Efficacy of Zidesamtinib

Alexander Drilon, MD, presents findings from the phase I/II ARROS-1 trial, which investigated the safety and efficacy of zidesamtinib—an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing—in patients with ROS1 fusion–positive non–small cell lung cancer (NSCLC) who experienced disease progression after previous treatment with a TKI (Abstract PL02.15). 

Lung Cancer

Jonathan Spicer, MD, PhD, on Perioperative Immunotherapy for Resectable NSCLC: HRQoL Outcomes

Jonathan D. Spicer, MD, PhD, of McGill University Health Centre, discusses health-related quality of life (HRQoL) findings from the CheckMate 77T trial. The analysis determined that receipt of perioperative nivolumab does not result in worse HRQoL outcomes vs placebo in patients with resectable non–small cell lung cancer (NSCLC), regardless of nodal status (Abstract MA04.05).

Lung Cancer

John M. Varlotto, MD, on Concurrent and Consolidation Durvalumab for Unresectable Stage III NSCLC

John M. Varlotto, MD, presents results from the phase III EA5181 trial (from the ECOG-ACRIN Cancer Research Group), which evaluated concurrent and consolidation durvalumab vs consolidation durvalumab alone for patients with unresectable stage III non–small cell lung cancer (NSCLC) (Abstract PL03.04). 

Lung Cancer

David Gerber, MD, on ALK-Positive NSCLC: Crizotinib vs Observation for Surgically Resected Early-Stage Disease

David Gerber, MD, of UT Southwestern Medical Center, reviews findings from the phase III E4512 trial, which evaluated the hypothesis that postoperative crizotinib may improve disease-free survival in patients with surgically resected ALK-positive non–small cell lung cancer (NSCLC), based on the drug’s efficacy and regulatory approval in advanced ALK-positive NSCLC (Abstract PL02.18). 

Lung Cancer

Gerrina Ruiter, MD, PhD, on Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Baseline Brain Metastases

Gerrina Ruiter, MD, PhD, of the Netherlands Cancer Institute, discusses data from the Beamion LUNG-1 trial, which is evaluating zongertiniban irreversible tyrosine kinase inhibitor that selectively inhibits HER2 while sparing EGFRin patients with HER2-mutant advanced or metastatic non–small cell lung cancer (NSCLC). This analysis of the trial focused on previously treated patients with active brain metastases (cohort 4) or stable/asymptomatic brain metastases (cohort 1) at baseline (Abstract PT2.12.03).

Advertisement

Advertisement




Advertisement